A pharmaceutical composition and its use
Through a pharmaceutical composition containing flavonoids, alkaloids, limoncilins and cyclolefins, the problem of insignificant efficacy of traditional Chinese medicine in treating upper respiratory tract infections is solved, and significant antiviral and anti-inflammatory effects are achieved. , suitable for clinical needs of traditional Chinese medicine and quality control of traditional Chinese patent medicines.
Patent Information
- Application Number
- CN202310773604.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-06-28
AI Technical Summary
The prior art is difficult to effectively treat upper respiratory tract infections, especially the medicinal substance basis of traditional Chinese medicine is unclear, and it is difficult to find effective Chinese medicine sites with significant therapeutic effects.
Provided is a pharmaceutical composition comprising flavonoids, alkaloids, limoncilins and cycloalether terpenes, which act synergistically to exert antiviral and anti-inflammatory activities through a combination of specific proportions, and are used to treat upper respiratory tract infections. .
This pharmaceutical composition has significant antiviral and anti-inflammatory effects, can effectively treat upper respiratory tract infections, has a clear foundation of drug effect, meets the actual clinical needs of traditional Chinese medicine, and can be used as standard extracts or control extracts for quality control of traditional Chinese patent medicines. .
Smart Images

Figure CN117462571B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of pharmaceutical chemistry technology, and in particular to a pharmaceutical composition and its use. Background Art
[0002] In clinical treatment of viral fever, traditional Chinese medicine mainly adopts methods such as relieving the exterior symptoms with pungent and cool herbs, relieving the exterior symptoms with pungent and warm herbs, relieving the exterior symptoms with clearing away heat and dampness, clearing the lungs and relieving heat, clearing away heat and detoxifying, relieving sore throat and reducing swelling, and clearing qi and cooling blood. Commonly used herbs for clearing heat and detoxifying include Radix Isatidis, Andrographis paniculata, Coptis chinensis, Scutellaria baicalensis, Taraxacum mongolicum, Herba Corydalis, Folium Isatidis, Fructus Arctii, Rhizoma Anemarrhenae, Sterculia lychnophorae, Fructus Aurantii Immaturus, Notopterygium wilfordii, Mentha, Rhizoma Phragmites, Rhubarb, Flos Lonicerae, etc., which have the functions of clearing heat and detoxifying, cooling blood and reducing swelling.
[0003] The clinical application of traditional Chinese medicine emphasizes overall regulation and syndrome differentiation, and has the characteristics of multi-component and multi-target integration. However, the material basis of the efficacy of traditional Chinese medicine is difficult to clarify. It is necessary to use modern science to study the efficacy of traditional Chinese medicine and establish a theoretical and technical system for the discovery of active components that conform to the overall characteristics of traditional Chinese medicine. In the complex chemical system of traditional Chinese medicine, it is necessary to find out which components can characterize the efficacy of traditional Chinese medicine, which equivalent component groups are equivalent to the efficacy of the original traditional Chinese medicine for a certain disease, and which are the core effective parts of traditional Chinese medicine. These studies are fundamental problems that need to be solved urgently in the basic research of traditional Chinese medicine. Using modern technology and means, extracting each active part for efficacy activity screening and safety evaluation, scientifically formulating according to the synergistic effect of different active parts on the efficacy, and then developing a modern traditional Chinese medicine compound preparation with distinct efficacy characteristics and based on the effective part group of traditional Chinese medicine has become one of the directions of research and development of modern traditional Chinese medicine compound preparations. At this stage, it is necessary to find an effective part group that can meet the characteristics of traditional Chinese medicine and has significant efficacy and can treat upper respiratory tract infections to meet clinical needs. Summary of the invention
[0004] The purpose of this application is to provide a pharmaceutical composition that is in accordance with the clinical practice of traditional Chinese medicine and has significant therapeutic effects and is composed of a certain proportion of effective parts of traditional Chinese medicine. The specific technical solution is as follows:
[0005] The first aspect of the present application provides a pharmaceutical composition, which comprises: 12-50 parts by weight of flavonoids, 0.7-7 parts by weight of alkaloids, 0.5-3.5 parts by weight of limonoids, and 38-100 parts by weight of iridoid glycosides.
[0006] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, and 38-90 parts by weight of iridoid glycosides;
[0007] Preferably, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 1-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, and 45-75 parts by weight of iridoid glycosides.
[0008] In some embodiments of the present application, the pharmaceutical composition further comprises: 0.4-3 parts by weight of organic acids and / or 5-50 parts by weight of sugars;
[0009] Preferably, the pharmaceutical composition further comprises: 0.4-1.5 parts by weight of organic acids and / or 5-25 parts by weight of sugars;
[0010] More preferably, the pharmaceutical composition further comprises: 0.4-1.3 parts by weight of organic acids and / or 5-18 parts by weight of sugars.
[0011] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, 38-90 parts by weight of iridoid glycosides, and 0.4-1.5 parts by weight of organic acids;
[0012] Preferably, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, 45-75 parts by weight of iridoid glycosides, and 0.4-1.3 parts by weight of organic acids;
[0013] More preferably, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.50-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, and 0.49-1.30 parts by weight of organic acids.
[0014] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, 38-90 parts by weight of iridoid glycosides, and 5-25 parts by weight of sugars;
[0015] Preferably, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, 45-75 parts by weight of iridoid glycosides, and 5-18 parts by weight of sugars.
[0016] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, 38-90 parts by weight of iridoid glycosides, 0.4-1.5 parts by weight of organic acids, and 5-25 parts by weight of sugars;
[0017] Preferably, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 1-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, 45-75 parts by weight of iridoid glycosides, 0.4-1.3 parts by weight of organic acids, and 5-18 parts by weight of sugars;
[0018] More preferably, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars.
[0019] In some embodiments of the present application, the flavonoids include at least one of baicalein, baicalin, wogonin, rutin and melaleucain A;
[0020] Preferably, the flavonoids comprise baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A in a weight ratio of (0.025-0.1):(0.08-1.4):(0.03-0.06):(0.01-0.03):(0.005-0.02);
[0021] More preferably, the flavonoids comprise baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.01).
[0022] In some embodiments of the present application, the flavonoids further comprise at least one of chrysin-7-O-β-D-glucuronide, isoquercetin, scutellarin, baicalin, baicalin II and calycosin;
[0023] Preferably, the weight ratio of baicalin to chrysin-7-O-β-D-glucuronide is (0.08-1.4):(0.01-0.03), preferably 1:(0.01-0.03); and / or
[0024] The weight ratio of baicalin to isoquercetin is (0.08-1.4):(0.002-0.007), preferably 1:(0.002-0.007); and / or
[0025] The weight ratio of baicalin to scutellariae is (0.08-1.4):(0.004-0.02), preferably 1:(0.004-0.02); and / or
[0026] The weight ratio of baicalin to baicalin II is (0.08-1.4): (0.008-0.02); preferably 1: (0.008-0.02); and / or
[0027] The weight ratio of baicalin to calycosin is (0.08-1.4):(0.004-0.01), preferably 1:(0.004-0.01).
[0028] In some embodiments of the present application, the flavonoids include baicalein, baicalin, wogonin, rutin, melaleucatin A, chrysin-7-O-β-D-glucuronide, baicalin II and calycosin in a weight ratio of (0.025-0.1): (0.08-1.4): (0.03-0.06): (0.01-0.03): (0.005-0.02): (0.01-0.03): (0.008-0.02): (0.004-0.01);
[0029] Preferably, the flavonoids contain baicalein, baicalin, wogonin, rutin, melaleuca alternifolia A, chrysin-7-O-β-D-glucuronide, isoquercitrin, baicalin, baicalin II and calycosin in a weight ratio of (0.025-0.1):(0.08-1.4):(0.03-0.06):(0.01-0.03):(0.005-0.02):(0.01-0.03):(0.002-0.007):(0.004-0.02):(0.008-0.02):(0.004-0.01).
[0030] In some embodiments of the present application, the alkaloids include at least one of berberine hydrochloride and adenosine;
[0031] Preferably, the weight ratio of berberine hydrochloride to adenosine is (0.5-1.5):(0.7-5.0), preferably 1:(0.7-5.0).
[0032] In some embodiments of the present application, the alkaloids further comprise indirubin, and the weight ratio of berberine hydrochloride to indirubin is (0.5-1.5): (0.005-0.12);
[0033] Preferably, the weight ratio of berberine hydrochloride, adenosine and indirubin is (0.5-1.5):(0.7-5.0):(0.005-0.12), preferably 1:(0.735-5.0):(0.005-0.12).
[0034] In some embodiments of the present application, the alkaloids further comprise at least one of phellodendrine hydrochloride, magnolamine, bamipine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine;
[0035] Preferably, the weight ratio of berberine hydrochloride to phellodendron hydrochloride is (0.5-1.5):(0.5-5), preferably 1:(0.5-4.5); and / or
[0036] The weight ratio of berberine hydrochloride to magnolia alkaloids is (0.5-1.5):(0.4-3.5), preferably 1:(0.4-3.5); and / or
[0037] The weight ratio of berberine hydrochloride to palmatine hydrochloride is (0.5-1.5):(0.02-0.2), preferably 1:(0.024-0.2); and / or
[0038] The weight ratio of berberine hydrochloride to jatrorrhizine hydrochloride is (0.5-1.5):(0.01-0.2), preferably 1:(0.015-0.15); and / or
[0039] The weight ratio of berberine hydrochloride to uridine is (0.5-1.5):(0.3-2.5), preferably 1:(0.35-2.5); and / or
[0040] The weight ratio of berberine hydrochloride to guanosine is (0.5-1.5):(0.3-2.0), preferably 1:(0.33-2.0).
[0041] In some embodiments of the present application, the alkaloids include berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of (0.5-1.5): (0.7-5.0): (0.005-0.12): (0.5-5): (0.4-3.5): (0.02-0.2): (0.01-0.2): (0.3-2.5): (0.3-2.0);
[0042] Preferably, the alkaloids comprise berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of 1: (0.735-5.0): (0.005-0.12): (0.5-4.5): (0.4-3.5): (0.024-0.2): (0.015-0.15): (0.35-2.5): (0.33-2.0);
[0043] More preferably, the alkaloids comprise berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of 1: (0.735-4.3): (0.005-0.12): (0.669-4.37): (0.446-3.13): (0.024-0.16): (0.019-0.135): (0.38-2.447): (0.33-1.898).
[0044] In some embodiments of the present application, the limonoids include at least one of limonin and obacillus ketone;
[0045] Preferably, the weight ratio of limonin to obacillus ketone is (10-30):(0-1.1), preferably (12-28.5):1.
[0046] In some embodiments of the present application, the iridoid glycosides include geniposide.
[0047] In some embodiments of the present application, the organic acid comprises at least one of chlorogenic acid, ferulic acid and benzoic acid;
[0048] Preferably, the weight percentage of chlorogenic acid in the organic acids is ≤100%, preferably ≤92%;
[0049] More preferably, the organic acids comprise chlorogenic acid and ferulic acid in a weight ratio of (4-12):(0.8-1.2);
[0050] More preferably, the organic acids comprise chlorogenic acid and ferulic acid in a weight ratio of (4-12):1.
[0051] In some embodiments of the present application, the carbohydrate comprises oligosaccharides; preferably, the oligosaccharides comprise stachyose.
[0052] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, and 49.07-74.99 parts by weight of iridoid glycosides; wherein the flavonoids comprise baicalein, baicalin, wogonin, rutin, and melaleucain A in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02); the alkaloids comprise berberine hydrochloride and adenosine in a weight ratio of 1:(1.0-5.0); the limonoids comprise limonin; and the iridoid glycosides comprise gardeniain;
[0053] Preferably, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the weight ratio of the flavonoids is (0.025-0.1):1:(0.03-0.06):(0. 01-0.03):(0.005-0.02) of baicalein, baicalin, wogonin, rutin and melaleuca A; the alkaloids contain berberine hydrochloride, adenosine and indirubin in a weight ratio of 1:(1.0-5.0):(0.01-0.1); the limonoids contain limonin and berberine in a weight ratio of (12-27):1; the iridoid glycosides contain gardenia glycoside; the organic acids contain chlorogenic acid; the sugars contain stachyose;
[0054] Preferably, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the weight ratio of the flavonoids is (0.02 5-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02):(0.01-0.03):(0.002-0.007):(0.004-0.02):(0.008-0.02):(0.004-0.01) of baicalin, baicalin, wogonin, rutin, melaleucalycin A, chrysin -7-O-β-D-glucuronide, isoquercetin, scutellarin, baicalin II and calycosin; the alkaloids contain a weight ratio of 1: (0.735-5.0): (0.005-0.12): (0.5-4.5): (0.4-3.5): (0.024-0.2): (0.015-0.15): (0.35-2.5): (0 .33-2.0) of berberine hydrochloride, adenosine, indirubin, phellodendron hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine; the limonoids contain limonin and phellodendron ketone in a weight ratio of (12-28.5):1; the iridoid glycosides contain gardenia glycoside; the organic acids contain chlorogenic acid and ferulic acid in a weight ratio of (4-12):1; the sugars contain stachyose;
[0055] Preferably, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the flavonoid component comprises baicalein, baicalin, wogonin, rutin, melaleuca alternifolia A, chrysin-7-O-β-D-glucose in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02):(0.01-0.03):(0.008-0.02):(0.004-0.01). glucuronic acid glycoside, scutellaria baicalensis flavonoids II and calycosin isoflavones; the alkaloids contain berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of 1: (0.7-5.0): (0.005-0.12): (0.5-5): (0.4-3.5): (0.02-0.20): (0.01-0.2): (0.3-2.5): (0.3-2.0); the limonoids contain limonin and phellodendronone in a weight ratio of (10-30): (0-1.1); the iridoid glycosides contain gardenia glycosides; the organic acids contain chlorogenic acid and ferulic acid in a weight ratio of (4-12): (0.8-1.2); the sugars contain stachyose.
[0056] In some embodiments of the present application, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient;
[0057] Preferably, the pharmaceutical composition can be made into a pharmaceutically acceptable preparation, and the dosage form of the preparation includes capsules, oral liquids, tablets, granules or pills.
[0058] The second aspect of the present application provides the use of the pharmaceutical composition described in the first aspect of the present application in preparing a drug for preventing and / or treating upper respiratory tract infection;
[0059] Preferably, the upper respiratory tract infection includes colds, pharyngitis, laryngitis, pharyngitis, and tonsillitis; wherein the pharyngitis includes acute pharyngitis, chronic pharyngitis, viral pharyngitis, and bacterial pharyngitis; the laryngitis includes acute laryngitis, chronic laryngitis, viral laryngitis, and bacterial laryngitis; the pharyngitis includes herpetic pharyngitis; the tonsillitis includes acute tonsillitis, chronic tonsillitis, viral tonsillitis, and bacterial tonsillitis.
[0060] The third aspect of the present application provides use of the pharmaceutical composition described in the first aspect of the present application in controlling the quality of traditional Chinese medicines; preferably, the pharmaceutical composition is used as a standard extract or a control extract.
[0061] The pharmaceutical composition provided by the present application is composed of a group of effective parts of traditional Chinese medicine in a certain proportion. By adopting limonoids, sugars and / or organic acids, it works in coordination with flavonoids, alkaloids and cyclopentane glycosides to exert their effects. It has good antiviral and anti-inflammatory activities and has the effect of treating upper respiratory tract infections. The material basis of the efficacy is clear, conforms to the clinical practice of traditional Chinese medicine, and can meet clinical needs. In addition, the pharmaceutical composition of the present application can be used as a standard extract or a control extract for the quality standard and quality control of Chinese patent medicines.
[0062] Of course, implementing any product or method of the present application does not necessarily require achieving all of the advantages described above at the same time. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application, and for ordinary technicians in this field, other embodiments can also be obtained based on these drawings.
[0064] Figure 1 This is a diagram showing the changes in RAW264.7 cell morphology (×200 times) after lipopolysaccharide (LPS) stimulation in anti-inflammatory cell experiment 1 and administration of the pharmaceutical composition of Examples 7-8.
[0065] Figure 2 This is a graph showing the changes in NO content in RAW264.7 cells after lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Example 7-8 in the anti-inflammatory cell experiment 1. ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (LPS) (p < 0.01).
[0066] Figure 3 This is a graph showing the changes in the content of inflammatory factor IL-6 in RAW264.7 cells after lipopolysaccharide (LPS) stimulation detected by ELISA in the anti-inflammatory cell experiment 1 and administration of the pharmaceutical composition of Examples 7-8.
[0067] Figure 4 This is a graph showing the changes in the content of the inflammatory factor IL-1β in RAW264.7 cells after lipopolysaccharide (LPS) stimulation detected by ELISA in the anti-inflammatory cell experiment 1 and administration of the pharmaceutical composition of Examples 7-8.
[0068] Figure 5 This is a graph showing the changes in the content of inflammatory factor TNF-α in RAW264.7 cells after lipopolysaccharide (LPS) stimulation detected by ELISA in the anti-inflammatory cell experiment 1 and administration of the pharmaceutical composition of Examples 7-8.
[0069] Figures 3 to 5 In the table, ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (LPS) (p < 0.01).
[0070] Figure 6 This is a graph of the Western blot analysis of the phosphorylation levels of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 proteins in RAW264.7 cells after lipopolysaccharide (LPS) stimulation in the anti-inflammatory cell experiment one.
[0071] Figure 7 This is the quantitative analysis of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 proteins in RAW264.7 cells after lipopolysaccharide (LPS) stimulation by Western blot in anti-inflammatory cell experiment 1. ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (LPS) (p < 0.01), and # indicates compared with the model group (LPS) (p < 0.05).
[0072] Figure 8 This is a diagram showing the changes in RAW264.7 cell morphology (×200 times) after lipopolysaccharide (LPS) stimulation in the anti-inflammatory cell experiment 2 and administration of the pharmaceutical composition of Examples 1-6.
[0073] Fig. 9 This is a graph showing the changes in NO content in RAW264.7 cells after lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 1-6 in the inflammatory cell experiment 2. ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (LPS) (p < 0.01).
[0074] Fig.10 This is a graph showing the changes in the content of inflammatory factor IL-6 in RAW264.7 cells after lipopolysaccharide (LPS) stimulation detected by ELISA in the anti-inflammatory cell experiment 2 and administration of the pharmaceutical composition of Examples 1-6.
[0075] Fig.11 This is a graph showing the changes in the content of the inflammatory factor IL-1β in RAW264.7 cells after lipopolysaccharide (LPS) stimulation detected by ELISA in the anti-inflammatory cell experiment 2 and administration of the pharmaceutical composition of Examples 1-6.
[0076] Fig.12 This is a graph showing changes in the content of inflammatory factor TNF-α in RAW264.7 cells after lipopolysaccharide (LPS) stimulation detected by ELISA in the anti-inflammatory cell experiment 2 and administration of the pharmaceutical composition of Examples 1-6.
[0077] Figures 10 to 12In the table, ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (LPS) (p < 0.01); # indicates compared with the model group (LPS) (p < 0.05).
[0078] Fig.13 This is a diagram showing the effects of the drug group on the pharyngeal mucosa of rats with acute pharyngitis in the pharyngitis animal experiment.
[0079] Fig.14 This is a statistical chart of the apparent score of the rat pharynx in the pharyngitis animal experiment. ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (AP) (p < 0.01); ns indicates no significant difference.
[0080] Fig.15 This is a graph showing the effect of the drug group on the serum inflammatory factor IL-6 in rats with acute pharyngitis in the pharyngitis animal experiment.
[0081] Fig.16 This is a graph showing the effect of the drug group on the serum inflammatory factor IL-1β in rats with acute pharyngitis in the pharyngitis animal experiment.
[0082] Fig.17 This is a graph showing the effect of the drug group on the serum inflammatory factor TNF-α in rats with acute pharyngitis in the pharyngitis animal experiment.
[0083] Figures 15 to 17 In the table, ** indicates compared with the blank group (NC) (p < 0.01); ## indicates compared with the model group (AP) (p < 0.01); # indicates compared with the model group (AP) (p < 0.05); ns indicates no significant difference.
[0084] Fig.18 This is a pathological section of the pharyngeal tissue of rats with acute pharyngitis in the pharyngitis animal experiment.
[0085] Fig.19 This is a graph showing the phosphorylation levels of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 proteins in the pharyngeal tissue of rats with acute pharyngitis analyzed by Western blot in a pharyngitis animal experiment.
[0086] Fig. 20 This is a quantitative diagram of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 protein in the pharyngeal tissue of rats with acute pharyngitis analyzed by Western blot in the pharyngeal animal experiment. ** indicates compared with the blank group (NC) (p < 0.01), * indicates compared with the blank group (NC) (p < 0.05); ## indicates compared with the model group (AP) (p < 0.01), # indicates compared with the model group (AP) (p < 0.05); ns indicates no significant difference. DETAILED DESCRIPTION
[0087] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments. All other embodiments obtained by those skilled in the art based on the present application belong to the scope of protection of the present application.
[0088] The first aspect of the present application provides a pharmaceutical composition, which comprises: 12-50 parts by weight of flavonoids, 0.7-7 parts by weight of alkaloids, 0.5-3.5 parts by weight of limonoids, and 38-100 parts by weight of iridoid glycosides.
[0089] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, and 38-90 parts by weight of iridoid glycosides.
[0090] In some embodiments of the present application, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 1-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, and 45-75 parts by weight of iridoid glycosides.
[0091] In some embodiments of the present application, the pharmaceutical composition further comprises: 0.4-3 parts by weight of organic acids and / or 5-50 parts by weight of sugars.
[0092] In some embodiments of the present application, the pharmaceutical composition further comprises: 0.4-1.5 parts by weight of organic acids and / or 5-25 parts by weight of sugars.
[0093] In some embodiments of the present application, the pharmaceutical composition further comprises: 0.4-1.3 parts by weight of organic acids and / or 5-18 parts by weight of sugars.
[0094] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, 38-90 parts by weight of iridoid glycosides, and 0.4-1.5 parts by weight of organic acids.
[0095] In some embodiments of the present application, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, 45-75 parts by weight of iridoid glycosides, and 0.4-1.3 parts by weight of organic acids.
[0096] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.50-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of cyclopentane glycosides, and 0.49-1.30 parts by weight of organic acids.
[0097] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, 38-90 parts by weight of iridoid glycosides, and 5-25 parts by weight of sugars.
[0098] In some embodiments of the present application, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, 45-75 parts by weight of iridoid glycosides, and 5-18 parts by weight of sugars.
[0099] In some embodiments of the present application, the pharmaceutical composition comprises: 15-35 parts by weight of flavonoids, 0.7-5 parts by weight of alkaloids, 0.5-2.0 parts by weight of limonoids, 38-90 parts by weight of cyclopentane glycosides, 0.4-1.5 parts by weight of organic acids, and 5-25 parts by weight of sugars.
[0100] In some embodiments of the present application, the pharmaceutical composition comprises: 20-33 parts by weight of flavonoids, 1-5 parts by weight of alkaloids, 0.5-1.5 parts by weight of limonoids, 45-75 parts by weight of cyclopentane glycosides, 0.4-1.3 parts by weight of organic acids, and 5-18 parts by weight of sugars.
[0101] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of cyclopentane glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars.
[0102] In some embodiments of the present application, the flavonoids include at least one of baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A.
[0103] In some embodiments of the present application, the flavonoids include baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A in a weight ratio of (0.025-0.1):(0.08-1.4):(0.03-0.06):(0.01-0.03):(0.005-0.02).
[0104] In some embodiments of the present application, the flavonoids include baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.01).
[0105] In some embodiments of the present application, the flavonoids further include at least one of chrysin-7-O-β-D-glucuronide, isoquercetin, scutellarin, baicalin, baicalin II and calycosin.
[0106] In some embodiments of the present application, the weight ratio of baicalin to chrysin-7-O-β-D-glucuronide is (0.08-1.4):(0.01-0.03), preferably 1:(0.01-0.03); and / or
[0107] The weight ratio of baicalin to isoquercetin is (0.08-1.4):(0.002-0.007), preferably 1:(0.002-0.007); and / or
[0108] The weight ratio of baicalin to scutellariae is (0.08-1.4):(0.004-0.02), preferably 1:(0.004-0.02); and / or
[0109] The weight ratio of baicalin to baicalin II is (0.08-1.4): (0.008-0.02); preferably 1: (0.008-0.02); and / or
[0110] The weight ratio of baicalin to calycosin is (0.08-1.4):(0.004-0.01), preferably 1:(0.004-0.01).
[0111] In some embodiments of the present application, the flavonoids include baicalin, baicalin, wogonin, rutin, melaleucalycin A, chrysin-7-O-β-D-glucuronide, baicalin II and calycosin in a weight ratio of (0.025-0.1): (0.08-1.4): (0.03-0.06): (0.01-0.03): (0.005-0.02): (0.01-0.03): (0.008-0.02): (0.004-0.01).
[0112] In some embodiments of the present application, the flavonoids include baicalin, baicalin, wogonin, rutin, melaleuca alternifolia A, chrysin-7-O-β-D-glucuronide, isoquercitrin, baicalin, baicalin II and calycosin in a weight ratio of (0.025-0.1): (0.08-1.4): (0.03-0.06): (0.01-0.03): (0.005-0.02): (0.01-0.03): (0.002-0.007): (0.004-0.02): (0.008-0.02): (0.004-0.01).
[0113] In some embodiments of the present application, the alkaloids include at least one of berberine hydrochloride and adenosine.
[0114] In some embodiments of the present application, the weight ratio of berberine hydrochloride to adenosine is (0.5-1.5):(0.7-5.0), preferably 1:(0.7-5.0).
[0115] In some embodiments of the present application, the alkaloids further comprise indirubin, and the weight ratio of berberine hydrochloride to indirubin is (0.5-1.5): (0.005-0.12).
[0116] In some embodiments of the present application, the weight ratio of berberine hydrochloride, adenosine and indirubin is (0.5-1.5):(0.7-5.0):(0.005-0.12), preferably 1:(0.735-5.0):(0.005-0.12).
[0117] In some embodiments of the present application, the alkaloids further comprise at least one of phellodendrine hydrochloride, magnolialine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine.
[0118] In some embodiments of the present application, the weight ratio of berberine hydrochloride to phellodendron hydrochloride is (0.5-1.5): (0.5-5), preferably 1: (0.5-4.5); and / or
[0119] The weight ratio of berberine hydrochloride to magnolia alkaloids is (0.5-1.5):(0.4-3.5), preferably 1:(0.4-3.5); and / or
[0120] The weight ratio of berberine hydrochloride to palmatine hydrochloride is (0.5-1.5):(0.02-0.2), preferably 1:(0.024-0.2); and / or
[0121] The weight ratio of berberine hydrochloride to jatrorrhizine hydrochloride is (0.5-1.5):(0.01-0.2), preferably 1:(0.015-0.15); and / or
[0122] The weight ratio of berberine hydrochloride to uridine is (0.5-1.5):(0.3-2.5), preferably 1:(0.35-2.5); and / or
[0123] The weight ratio of berberine hydrochloride to guanosine is (0.5-1.5):(0.3-2.0), preferably 1:(0.33-2.0).
[0124] In some embodiments of the present application, the alkaloids include berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of (0.5-1.5): (0.7-5.0): (0.005-0.12): (0.5-5): (0.4-3.5): (0.02-0.2): (0.01-0.2): (0.3-2.5): (0.3-2.0).
[0125] In some embodiments of the present application, the alkaloids include berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of 1: (0.735-5.0): (0.005-0.12): (0.5-4.5): (0.4-3.5): (0.024-0.2): (0.015-0.15): (0.35-2.5): (0.33-2.0).
[0126] In some embodiments of the present application, the alkaloids include berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of 1: (0.735-4.3): (0.005-0.12): (0.669-4.37): (0.446-3.13): (0.024-0.16): (0.019-0.135): (0.38-2.447): (0.33-1.898).
[0127] In some embodiments of the present application, the limonoids include at least one of limonin and obacillus ketone.
[0128] In some embodiments of the present application, the weight ratio of limonin to obacillus ketone is (10-30):(0-1.1), preferably (12-28.5):1.
[0129] In some embodiments of the present application, the iridoid glycosides include geniposide.
[0130] In some embodiments of the present application, the organic acid comprises at least one of chlorogenic acid, ferulic acid and benzoic acid.
[0131] In some embodiments of the present application, the weight percentage of chlorogenic acid in organic acids is ≤100%, preferably ≤92%.
[0132] In some embodiments of the present application, the organic acid comprises chlorogenic acid and ferulic acid in a weight ratio of (4-12):(0.8-1.2).
[0133] In some embodiments of the present application, the organic acid comprises chlorogenic acid and ferulic acid in a weight ratio of (4-12):1.
[0134] In some embodiments of the present application, the carbohydrate comprises oligosaccharides.
[0135] In some embodiments of the present application, the oligosaccharide comprises stachyose.
[0136] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, and 49.07-74.99 parts by weight of iridoid glycosides; wherein the flavonoids comprise baicalein, baicalin, wogonin, rutin and melaleucain A in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02); the alkaloids comprise berberine hydrochloride and adenosine in a weight ratio of 1:(1.0-5.0); the limonoids comprise limonin; and the iridoid glycosides comprise gardeniain.
[0137] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the weight ratio of flavonoids is (0.025-0.1):1:(0.03-0. 06): (0.01-0.03): (0.005-0.02) of baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A; alkaloids include berberine hydrochloride, adenosine and indirubin in a weight ratio of 1: (1.0-5.0): (0.01-0.1); limonoids include limonin and berberine in a weight ratio of (12-27): 1; iridoid glycosides include gardenia glycoside; organic acids include chlorogenic acid; sugars include stachyose.
[0138] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the flavonoids comprise a weight ratio of Baicalein, baicalin, wogonin, rutin, melaleuca alternifolia, baicalin ... Paper A, chrysin-7-O-β-D-glucuronide, isoquercetin, scutellarin, baicalin II and calycosin; alkaloids contain weight ratio of 1: (0.735-5.0): (0.005-0.12): (0.5-4.5): (0.4-3.5): (0.024-0.2): (0.015-0.15): (0.35-2 .5): (0.33-2.0) of berberine hydrochloride, adenosine, indirubin, phellodendron hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine; limonoids include limonin and phellodendron ketone in a weight ratio of (12-28.5): 1; iridoid glycosides include gardenia glycoside; organic acids include chlorogenic acid and ferulic acid in a weight ratio of (4-12): 1; sugars include stachyose.
[0139] In some embodiments of the present application, the pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the flavonoid component comprises baicalein, baicalin, wogonin, rutin, melaleuca alternifolia A, chrysin-7-ol in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02):(0.01-0.03):(0.008-0.02):(0.004-0.01). O-β-D-glucuronide, scutellaria baicalensis flavonoids II and calycosin isoflavones; alkaloids include berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine in a weight ratio of 1: (0.7-5.0): (0.005-0.12): (0.5-5): (0.4-3.5): (0.02-0.20): (0.01-0.2): (0.3-2.5): (0.3-2.0); limonoids include limonin and phellodendronone in a weight ratio of (10-30): (0-1.1); iridoid glycosides include gardenia glycosides; organic acids include chlorogenic acid and ferulic acid in a weight ratio of (4-12): (0.8-1.2); sugars include stachyose.
[0140] This application analyzes the ingredients of the formula, combines the identification and pharmacokinetics of metabolites in the body, and selects 45 small molecule compounds with pharmacodynamic activity (including 14 flavonoids and flavonoid glycosides, 6 iridoid glycosides, 7 benzylisoquinoline alkaloids, 4 sulfur-containing alkaloids, 2 indole alkaloids, 4 nucleosides, 2 phenylpropanoids, 2 limonin nortriterpenes, 2 crocin diterpenes, 1 monoterpenoid, and 1 oligosaccharide compound) for compatibility; by using specific components and specific proportions, the components work synergistically to obtain a pharmaceutical composition with good antiviral and anti-inflammatory activity and significant therapeutic effect on upper respiratory tract infection. The pharmaceutical composition of this application has a clear material basis for its efficacy and can meet clinical needs.
[0141] The present application has no restriction on the sources of the components gardenia glycoside, stachyose, baicalein, baicalin, wogonin, rutin, melaleucain A, chrysin-7-O-β-D-glucuronide, baicalin II, calycosin isoflavones, berberine hydrochloride, adenosine, indirubin, phellodendronine hydrochloride, magnolia alkaloids, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine, guanosine, limonin, phellodendron ketone, chlorogenic acid, ferulic acid, isoquercetin, and baicalin, which can be obtained by chemical synthesis process or extraction and purification of medicinal materials. The medicinal materials include but are not limited to at least one of Radix Isatidis, Radix Scutellariae, Gardenia, Phellodendron, Sterculia lychnophora, Taraxacum, Herba Corydalis, Andrographis paniculata, Coptis chinensis, Fructus Aurantii Immaturus, Notopterygium wilfordii, Mentha, Rhizoma Phragmites, Phellodendron, Rhubarb, Scutellariae, Flos Lonicerae, Folium Isatidis, Fructus Arcti, Rhizoma Anemarrhenae, Fructus Forsythiae, or Folium Perillae.
[0142] The preparation method of the pharmaceutical composition described in the present application can be: uniformly mixing the raw material components described in the first aspect of the present application to obtain the pharmaceutical composition.
[0143] The pharmaceutical composition described in the present application can also be prepared by the following method: decocting, heating to reflux or percolating at least one of the above-mentioned medicinal materials with water and / or alcohol to obtain an extract; and the extract is concentrated, purified and dried to obtain an extract containing the pharmaceutical composition described in the present application.
[0144] The pharmaceutical composition described in the present application can also be prepared by the following method: extracting the above medicinal materials with water and precipitating with alcohol, collecting the supernatant, concentrating and drying, and obtaining an extract containing the pharmaceutical composition described in the present application.
[0145] The pharmaceutical composition provided in the present application uses limonoids and / or sugars to cooperate with flavonoids, alkaloids and iridoid glycosides to exert their effects together, and has good antiviral and anti-inflammatory effects.
[0146] In some embodiments of the present application, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient, such as a solvent, a diluent, a disintegrant, a precipitation inhibitor, a surfactant, a glidant, a binder, a lubricant, a dispersant, a suspending agent, an isotonic agent, a thickener, an emulsifier, a preservative, a stabilizer, a hydrating agent, an emulsification accelerator, a buffer, an absorbent, a colorant, a flavoring agent, a sweetener, an ion exchanger, a release agent, a coating agent, a flavoring agent or an antioxidant, etc. Specifically, it may comprise dextrin, sucralose, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, sodium benzoate, Tween 80, polyethylene glycol 6000, polyethylene glycol 4000 or dimethyl silicone oil, etc.
[0147] In some embodiments of the present application, the pharmaceutical composition can be prepared into a pharmaceutically acceptable preparation, and the dosage form of the pharmaceutical composition includes but is not limited to capsules, oral liquids, tablets, granules or pills.
[0148] For example, add appropriate amounts of dextrin, sucralose, and magnesium stearate to the pharmaceutical composition described in the first aspect of the present application, dry granulate, and sieve the whole particles to obtain granules; add appropriate amounts of microcrystalline cellulose, sodium carboxymethyl starch, and magnesium stearate to the pharmaceutical combination described in the first aspect of the present application, mix evenly, and compress to obtain tablets; dissolve the pharmaceutical combination described in the first aspect of the present application in water, leave it overnight, add appropriate amounts of sodium benzoate and Tween 80 to mix evenly, add water to 1000 mL, stir evenly, boil, refrigerate, filter, adjust the pH to 6-7, package, and sterilize to obtain an oral solution; add appropriate amounts of polyethylene glycol 6000 and polyethylene glycol 4000 to the pharmaceutical combination described in the first aspect of the present application, heat to melt, stir evenly, drop them into a dimethyl silicone oil coolant, wash the pills, dry them, and select the pills to obtain drop pills.
[0149] The second aspect of the present application provides the use of the pharmaceutical composition described in the first aspect of the present application in the preparation of a drug for preventing and / or treating upper respiratory tract infection.
[0150] The third aspect of the present application provides a drug for preventing and / or treating upper respiratory tract infection; wherein the drug comprises the pharmaceutical composition described in the first aspect of the present application.
[0151] The fourth aspect of the present application provides a method for preventing and / or treating upper respiratory tract infection, comprising administering an effective dose of the pharmaceutical composition described in the first aspect of the present application to a subject in need thereof.
[0152] In some embodiments of the present application, upper respiratory tract infection includes colds, pharyngitis, laryngitis, pharyngitis, and tonsillitis; wherein pharyngitis includes acute pharyngitis, chronic pharyngitis, viral pharyngitis, and bacterial pharyngitis; laryngitis includes acute laryngitis, chronic laryngitis, viral laryngitis, and bacterial laryngitis; pharyngitis includes herpetic pharyngitis; tonsillitis includes acute tonsillitis, chronic tonsillitis, viral tonsillitis, and bacterial tonsillitis.
[0153] The fifth aspect of the present application provides the use of the pharmaceutical composition described in the first aspect of the present application in controlling the quality of Chinese patent medicines.
[0154] In some embodiments of the present application, the pharmaceutical composition is used as a standard extract or a control extract.
[0155] Example
[0156] The following examples are given to more specifically describe the embodiments of the present application. Various tests and evaluations were performed according to the following methods. In addition, unless otherwise specified, "parts" and "%" are based on mass.
[0157] Adenosine (98%), baicalein (98%), wogonin (98%), rutin (98%), berberine hydrochloride (98%), baicalin (98%), limonin (98%), oroxylin A (98%), geniposide (98%), obacunone (98%), stachyose (98%), chlorogenic acid (98%), indirubin (97%), isoquercitrin (98%), palmatine hydrochloride (98%), phellodendrine hydrochloride (98%), jatrorrhizine hydrochloride (98%) Hydrochloride, 98%), Scutellarin, 95%), and Ferulic acid, 98%) were purchased from Chengdu Pusi Biotechnology Co., Ltd.; Chrysin 7-O-β-D-glucopyranuronoside, 98%), Magnoflorine, 98%), and Calycosin, 98%) were purchased from Chengdu Munster Biotechnology Co., Ltd.; Skullcapflavone II, 98%) was purchased from ChemFaces; Uridine, 98%) and Guanosine, 98%) were purchased from Shanghai Yuanye Biotechnology Co., Ltd.
[0158] Example 1
[0159] Take 1479 mg of flavonoids, 76.8 mg of alkaloids, 40.4 mg of limonoids, 3854.7 mg of iridoid glycosides, 32.6 mg of organic acids, and 439.4 mg of sugars, wherein: flavonoids include 41.3 mg of baicalin, 1358.6 mg of baicalin, 46 mg of wogonin, 9.3 mg of melaleucain A, and 23.8 mg of rutin; alkaloids include 14.9 mg of berberine hydrochloride, 61.5 mg of adenosine, and 0.4 mg of indirubin; limonoids include 38.6 mg of limonoids and 1.8 mg of chlorogenic acid; iridoid glycosides include 3854.7 mg of gardenia glycosides; organic acids include 32.6 mg of chlorogenic acid; and sugars include 439.4 mg of stachyose. Mix the above ingredients evenly to obtain a pharmaceutical composition.
[0160] Example 2-Example 34
[0161] Except for adjusting the types of raw material components and the contents of each raw material component as shown in Table 1, Table 2 and Table 3, the rest is the same as Example 1.
[0162]
[0163]
[0164]
[0165]
[0166] Example 35-Example 68
[0167] 65% dextrin, 0.5% sucralose, and 1% magnesium stearate (based on the mass of the pharmaceutical composition as 100%) were added to the pharmaceutical compositions of Examples 1 to 34, respectively, mixed, dry granulated, and sieved to obtain granules.
[0168] Example 69-Example 102
[0169] 70% microcrystalline cellulose, 4% sodium carboxymethyl starch, and 0.5% magnesium stearate (based on the mass of the pharmaceutical composition as 100%) were added to the pharmaceutical compositions of Examples 1 to 34, respectively, mixed evenly, and compressed into tablets to obtain tablets.
[0170] Example 103-Example 136
[0171] Dissolve the pharmaceutical compositions of Examples 1 to 34 in water respectively, leave overnight, add 0.5% sodium benzoate and 1% Tween 80 (based on the mass of the pharmaceutical composition as 100%) and mix well, add water to 1000 mL, stir well, boil, refrigerate, filter, adjust the pH to 6-7, package, and sterilize to obtain an oral solution.
[0172] Example 137-Example 170
[0173] Weigh twice the mass of polyethylene glycol (polyethylene glycol includes polyethylene glycol 6000 and polyethylene glycol 4000 in a mass ratio of 3:1) of the pharmaceutical composition, heat to melt, add to the pharmaceutical composition of Example 1 to Example 34, stir evenly, drop into dimethyl silicone oil coolant, wash the pills, dry them, and select the pills to obtain the dropping pills.
[0174] Anti-inflammatory cell experiment 1
[0175] 1. Experimental Materials
[0176] 1. Experimental cells
[0177] RAW264.7 mouse macrophages (catalog number: TCM13) were purchased from the Cell Bank of Type Culture Collection Committee of the Chinese Academy of Sciences.
[0178] 2. Experimental reagents
[0179] Dexamethasone acetate (DXM) was purchased from Zhejiang Xianjun Pharmaceutical Co., Ltd.
[0180] Fetal bovine serum (FBS) was purchased from Gibco (Grand Island, USA).
[0181] DMEM medium containing double-antibody and high-glucose was purchased from Jiangsu KeyGen Biotech Co., Ltd.
[0182] Dimethyl sulfoxide (DMSO) and lipopolysaccharide (LPS) were purchased from Sigma.
[0183] Mouse tumor necrosis factor-α (TNF-α) ELISA kit (E-EL-M3063), mouse interleukin-6 (IL-6) ELISA kit (E-EL-M0044c), and mouse interleukin-1β (IL-1β) ELISA kit (E-EL-M0037) were purchased from Wuhan Eliorite Biotechnology Co., Ltd.
[0184] The CCK-8 detection kit was purchased from APExIBO.
[0185] BCA protein quantification kit, nitric oxide detection kit, Western and IP cell lysate were purchased from Shanghai Biotech Biotechnology Co., Ltd.
[0186] Protease inhibitors and phosphatase inhibitors were purchased from Shanghai Roche Pharmaceuticals Co., Ltd.
[0187] Skim milk powder was purchased from Inner Mongolia Yili Industrial Group Co., Ltd.
[0188] Nitrocellulose membrane NC was purchased from Millipore.
[0189] Protein markers were purchased from Nanjing Novozymes Biotechnology Co., Ltd.
[0190] Sodium dodecyl sulfate (SDS), Tris, 4×Tris-HCl (pH8.8), 4×Tris-HCl (pH6.8), ready-to-use TBS powder, glycine, ammonium persulfate, tetramethylethylenediamine (TEMED) and 30% acrylamide solution were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0191] Tween 20 was purchased from Nanjing Chemical Reagent Co., Ltd.
[0192] The primary antibodies TLR4 (mouse, sc-293072) and NF-κB p65 (mouse, sc-8008) were purchased from Santa Cruz Biotechnology.
[0193] Red loading buffer (3×, 7723) and primary antibody p-NF-κB p65 (Rabbit, 3033) were purchased from Cellsignaling technology.
[0194] Internal reference β-actin (Rabbit, 20536-1-AP), HRP-goat anti-rabbit IgG (SA00001-2) and HRP-goat anti-mouse IgG (SA00001-1) were purchased from Proteintech.
[0195] ECL chemiluminescent substrate was purchased from Shanghai Tianneng Technology Co., Ltd.
[0196] 3. Experimental instruments
[0197] BT25S one-hundred-thousandth balance (Sartorius, Gottingen, Germany); multifunctional microplate reader (BERTHOLD TECHNOLOGIES); fully automatic chemiluminescence / fluorescence image analysis system (Shanghai Tianneng Technology Co., Ltd.); HH-4 digital display constant temperature water bath (Guohua Electric Co., Ltd.); inverted fluorescence microscope (Nanjing Skospect Instrument Co., Ltd.); centrifuge (Thermo Fisher Scientific (China) Co., Ltd.); carbon dioxide cell culture incubator (Hereaus, Germany); biological safety cabinet (Thermo Fisher Scientific, USA).
[0198] 2. Experimental methods and results
[0199] Experimental groups: (1) blank group (NC); (2) model group (LPS); (3) ECS-1 group of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 7; (4) ECS-2 group of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 8; (5) positive drug (DXM) group: dexamethasone acetate.
[0200] Preparation of sample solution: (1) Culture medium: DMEM high-glucose culture medium containing 5 vol% fetal bovine serum (FBS) and antibiotics (100 U / mL penicillin, 100 μg / mL streptomycin).
[0201] Culture medium containing the pharmaceutical composition of Example 7: The pharmaceutical composition of Example 7 was added to 1000 mL of the above culture medium, wherein baicalein 0.1327 mg / mL, baicalin 2.150 mg / mL, wogonin 0.1182 mg / mL, melaleucatin A 0.0194 mg / mL, rutin 0.03661 mg / mL, berberine hydrochloride 0.02574 mg / mL, adenosine 0.088 mg / mL, indirubin 0.001540 mg / mL, limonin 0.09117 mg / mL, berberine 0.005180 mg / mL, gardenia glycoside 5.640 mg / mL, chlorogenic acid 0.06917 mg / mL, and stachyose 1.062 mg / mL.
[0202] Culture medium containing the pharmaceutical composition of Example 8: The pharmaceutical composition of Example 8 was added to 1000 mL of the above culture medium, wherein baicalein 0.1327 mg / mL, baicalin 2.150 mg / mL, wogonin 0.1182 mg / mL, melaleuca alternifolia A 0.0194 mg / mL, rutin 0.03661 mg / mL, berberine hydrochloride 0.02574 mg / mL, adenosine 0.088 mg / mL, limonin 0.09117 mg / mL, and gardenia glycoside 5.640 mg / mL.
[0203] Culture medium containing the pharmaceutical composition of DXM: DXM was added to 1000 mL of the above culture medium, wherein the final concentration of DXM was 4.4 μg / mL.
[0204] (2) Phosphate buffered saline (1× PBS): Dissolve the premixed powder in deionized water until the volume reaches 1 L, and sterilize.
[0205] Cell culture and passage: RAW264.7 cells were cultured in DMEM high-glucose medium containing 10 vol% fetal bovine serum (FBS) and antibiotics (100 U / mL penicillin, 100 μg / mL streptomycin) in an incubator with a CO volume fraction of 5%. 2 , temperature 37℃, observe the growth of cells every day, change the medium and pass the culture. When RAW264.7 cells grow to 80-90% confluence, discard the old cell culture medium, use a pipette to suck up new cell culture medium and add it, repeatedly and gently blow the cells attached to the wall to make them fall off and suspend, transfer to a 15mL centrifuge tube, centrifuge (1000rpm, 3min), discard the supernatant, add new culture medium, and repeatedly and gently blow to suspend. Then adjust the cells to 1:2-1:3 and inoculate them in a new culture dish, place it in a 5% CO 2 , and cultured in an incubator at 37°C. When the cells were in the logarithmic growth phase, various cell experiments were performed, and LPS (100 ng / mL) was used as an inflammation model group.
[0206] Data processing: GraphPad Prism 9.0 was used for statistical analysis of the data. The experimental results were expressed as mean ± standard error (mean ± SEM). The comparison between two groups of data was performed using the Student's t-test, and the comparison between multiple groups was performed using the one-way ANOVA. Differences with p < 0.05 were considered statistically significant ( * p<0.05, ** p<0.01; # p<0.05, ## p<0.01; ns=not significant).
[0207] 1. Changes in RAW264.7 cell morphology after LPS stimulation
[0208] A blank group (NC), a model group (LPS), an ECS-1 group of the pharmaceutical composition of the present application, an ECS-2 group of the pharmaceutical composition of the present application, and a dexamethasone acetate positive drug (DXM) group were set up, with 2 replicate wells in each group.
[0209] RAW264.7 cells were seeded in 6-well plates (1×10 6 cells / well), 2 mL per well, incubated at 37°C, 5% CO 2 After 24 hours of culture, the cell supernatant was discarded, 1800 μL of fresh culture medium was added to the NC group and LPS group, and the same volume of culture medium containing the corresponding drug was added to the ECS-1 group, ECS-2 group, and DXM group. After 2 hours, 200 μL of PBS was added to the NC group, and 200 μL of LPS (the final concentration of LPS was 100 ng / mL) was added to the LPS group, ECS-1 group, ECS-2 group, and DXM group. After 16 hours of co-culture, the cells were placed on an inverted fluorescence microscope to observe the changes in cell morphology and take pictures.
[0210] The experimental results are as follows Figure 1 As shown, Figure 1 Figure 2 is a diagram showing changes in the morphology of RAW264.7 cells after stimulation with lipopolysaccharide (LPS) and administration of the pharmaceutical composition of Example 7-8 (×200 times). Figure 1 It can be seen that compared with the NC group, the cell morphology of RAW264.7 cells in the LPS group changed after LPS-induced stimulation, the cells extended their antennae and showed a polarized state; compared with the LPS group, the cell morphology of the drug-treated groups (ECS-1 group, ECS-2 group and DXM group) improved to varying degrees; the above results indicate that different drug-treated groups can effectively improve the cell morphology of the LPS-induced inflammation model.
[0211] 2. Nitric oxide detection kit to test the changes in NO content in RAW264.7 cells after LPS stimulation
[0212] A blank group (NC), a model group (LPS), an ECS-1 group of the pharmaceutical composition of the present application, an ECS-2 group of the pharmaceutical composition of the present application, and a dexamethasone acetate positive drug group (DXM) were set up, with 8 replicate wells in each group.
[0213] RAW264.7 cells were seeded in 48-well plates (3×10 5 cells / well), 200 μL per well, incubate at 37°C, 5% CO 2 After 24 hours of culture, the cell supernatant was discarded, 180 μL of fresh culture medium was added to the NC group and LPS group, and the same volume of culture medium containing the corresponding drug was added to the ECS-1 group, ECS-2 group and DXM group. After 2 hours, 20 μL of PBS was added to the NC group, and 20 μL of LPS (the final concentration of LPS was 100 ng / mL) was added to the LPS group, ECS-1 group, ECS-2 group and DXM group. After 16 hours of co-culture, the cell supernatant was collected and centrifuged (1000×g, 20 min), the supernatant was taken, and then the NO content was tested according to the instructions of the nitric oxide detection kit.
[0214] The experimental results are as follows Figure 2 As shown, Figure 2 Figure 2 is a graph showing changes in NO content in RAW264.7 cells after lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Example 7-8. Figure 2 It can be seen that compared with the NC group, the amount of NO released in the LPS group was significantly increased, indicating that the inflammatory model was successfully constructed; compared with the LPS group, the expression levels of NO in the ECS-1 group, ECS-2 group and DXM group were reduced to varying degrees; the above results show that different drug administration groups can effectively inhibit the release of NO in the LPS-induced inflammatory model, thereby producing a good anti-inflammatory effect.
[0215] 3. ELISA method to detect the changes in the content of inflammatory factors in RAW264.7 cells after LPS stimulation
[0216] A blank group (NC), a model group (LPS), an ECS-1 group of the pharmaceutical composition of the present application, an ECS-2 group of the pharmaceutical composition of the present application, and a dexamethasone acetate positive drug (DXM) group were set up, with 8 replicate wells in each group.
[0217] RAW264.7 cells were seeded in 48-well plates (3×10 5 cells / well), 200 μL per well, incubate at 37°C, 5% CO 2The cells were cultured for 24 h, after which the cell supernatant was discarded. 180 μL of fresh culture medium was added to the NC group and the LPS group, and the same volume of culture medium containing the corresponding drugs was added to the ECS-1 group, the ECS-2 group, and the DXM group. After 2 h, 20 μL of PBS was added to the NC group, and 20 μL of LPS (the final concentration of LPS was 100 ng / mL) was added to the LPS group, the ECS-1 group, the ECS-2 group, and the DXM group. After 16 h of co-culture, the cell supernatant was collected and centrifuged (1000 × g, 20 min), the supernatant was taken, and then the content of each inflammatory factor was tested according to the instructions of the mouse IL-6, TNF-α, and IL-1β detection kit.
[0218] The expression of inflammatory factors IL-6, IL-1β, and TNF-α is an important indicator of acute pharyngitis. Figure 3-Figure 5 As shown, Figure 3 This is a graph showing changes in the content of inflammatory factor IL-6 in RAW264.7 cells after lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 7-8 by ELISA; Figure 4 This is a graph showing changes in the content of inflammatory factor IL-1β in RAW264.7 cells after ELISA detection of lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 7-8; Figure 5 The graph is a graph showing the changes in the content of inflammatory factor TNF-α in RAW264.7 cells after lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 7-8. Figure 3-Figure 5 It can be seen that: compared with the NC group, the contents of cellular inflammatory factors IL-6, IL-1β, and TNF-α in the LPS group were significantly higher than those in the blank group (p < 0.01), indicating that the inflammation model was successfully constructed; compared with the LPS group, the levels of cellular inflammatory factors IL-6, IL-1β, and TNF-α in the ECS-1 group, ECS-2 group, and DXM group were significantly reduced (p < 0.01). The above results indicate that the pharmaceutical composition provided in the present application can exert a good anti-inflammatory effect.
[0219] 4. Western blot analysis of the expression of related proteins in the TLR4 / NF-κB signaling pathway
[0220] A blank group (NC), a model group (LPS), an ECS-1 group of the pharmaceutical composition of the present application, an ECS-2 group of the pharmaceutical composition of the present application, and a dexamethasone acetate positive drug (DXM) group were set up, with 3 replicate wells in each group.
[0221] RAW264.7 cells were seeded in 6-well plates (1×10 6 cells / well), 2 mL per well, incubated at 37°C, 5% CO 2After 24 hours of culture, the cell supernatant was discarded, 1800 μL of fresh culture medium was added to the NC group and LPS group, and the same volume of culture medium containing the corresponding drugs was added to the ECS-1 group, ECS-2 group and DXM group. After 2 hours, 200 μL of PBS was added to the NC group, and 200 μL of LPS (the final concentration of LPS was 100 ng / mL) was added to the LPS group, ECS-1 group, ECS-2 group and DXM group. After 16 hours of co-culture, the cell culture supernatant was discarded and the cells were collected. 120 μL of cell lysis buffer (Western and IP cell lysis buffer: 100× protease inhibitor: 100× phosphatase inhibitor volume ratio was 100:1:1) was added to lyse on ice, and the lysate was centrifuged at 12000 r / min for 10 minutes in a pre-cooled centrifuge at 4°C, and the supernatant was taken. The protein concentration was determined by BCA protein quantification kit. After quantification, the protein samples were added with a certain proportion of 3× protein loading buffer to dilute the buffer to 1×, denatured at 100°C for 15 min, and stored at -80°C. The expression of β-actin, TLR4, NF-κB p65, and p-NF-κBp65 proteins in cells was detected by Western blot. According to the quantitative sample protein concentration, 10 μg of protein was loaded per well, electrophoresed at 80V for 30 min, then transferred to 120V for 1 h, transferred to 350 mA for 1 h, blocked with 5% (w / v) skim milk powder at 4°C, incubated at 4°C overnight after the primary antibody was diluted in proportion, washed with TBST buffer 3×10 min the next day, incubated at 4°C after the secondary antibody was diluted in proportion, washed with TBST buffer, added ECL supersensitive luminescent liquid, and exposed in the dark room to collect β-actin, TLR4, NF-κB p65, and p-NF-κB p65 protein signals.
[0222] The experimental results are as follows Figure 6 and Figure 7 As shown, Figure 6 This is a Western blot analysis of the phosphorylation levels of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 proteins in RAW264.7 cells after lipopolysaccharide (LPS) stimulation. Figure 7 This is a quantitative graph of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 proteins in RAW264.7 cells after lipopolysaccharide (LPS) stimulation analyzed by Western blot. Figure 7 p-NF-κB p65 / NF-κB p65 refers to the ratio of p-NF-κB p65 to NF-κB p65. β-actin is an internal reference, and the ratio is used to determine the amount of protein. Figure 6 and Figure 7It can be seen that lipopolysaccharide (LPS) can stimulate the significant upregulation of TLR4 and p-NF-κB p65 proteins in RAW264.7 cells (p < 0.01), and the administration of ECS-1, ECS-2 and DXM can inhibit the expression of TLR4 and p-NF-κB p65 proteins in RAW264.7 cells induced by LPS (p < 0.05). The above results indicate that the process by which the pharmaceutical composition provided in the present application exerts its anti-inflammatory effect is basically the same. Without being limited to any theory, the inventors of the present application believe that the anti-inflammatory effect of each component group in the pharmaceutical composition provided in the present application may be related to the inhibition of the TLR4 / NF-κB signaling pathway in RAW264.7 cells.
[0223] Anti-inflammatory cell experiment 2
[0224] 1. Experimental Materials
[0225] The experimental materials are the same as those of “Anti-inflammatory Cell Experiment 1”.
[0226] 2. Experimental methods and results
[0227] Experimental groups: (1) blank group (NC); (2) model group (LPS); (3) group 9+4-L of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 1; (4) group 9+4-M of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 2; (5) group 9+4-H of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 3; (6) group 9-L of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 4; (7) group 9-M of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 5; (8) group 9-H of the pharmaceutical composition of the present application: the pharmaceutical composition of Example 6; (9) positive drug (DXM) group: dexamethasone acetate.
[0228] Preparation of sample solution: (1) Culture medium: DMEM high-glucose culture medium containing 5 vol% fetal bovine serum (FBS) and antibiotics (100 U / mL penicillin, 100 μg / mL streptomycin).
[0229] Culture medium containing the pharmaceutical composition of Example 1: The pharmaceutical composition of Example 1 was added to 1000 mL of the above culture medium, wherein baicalein 0.0413 mg / mL, baicalin 1.3586 mg / mL, wogonin 0.046 mg / mL, melaleucatin A 0.0093 mg / mL, rutin 0.0238 mg / mL, berberine hydrochloride 0.0149 mg / mL, adenosine 0.0615 mg / mL, indirubin 0.0004 mg / mL, limonin 0.0386 mg / mL, chlorogenic acid 0.0018 mg / mL, gardenia glycoside 3.8547 mg / mL, chlorogenic acid 0.0326 mg / mL, and sugars including stachyose 0.4394 mg / mL.
[0230] Culture medium containing the pharmaceutical composition of Example 2: The pharmaceutical composition of Example 2 was added to 1000 mL of the above culture medium, wherein baicalein 0.1765 mg / mL, baicalin 2.3211 mg / mL, wogonin 0.0899 mg / mL, melaleucatin A 0.0196 mg / mL, rutin 0.0366 mg / mL, berberine hydrochloride 0.0257 mg / mL, adenosine 0.0880 mg / mL, indirubin 0.0015 mg / mL, limonin 0.0912 mg / mL, berberine 0.0052 mg / mL, gardenia glycoside 5.6389 mg / mL, chlorogenic acid 0.0692 mg / mL, and stachyose 1.0617 mg / mL.
[0231] Culture medium containing the pharmaceutical composition of Example 3: The pharmaceutical composition of Example 3 was added to 1000 mL of the above culture medium, wherein baicalein 0.2568 mg / mL, baicalin 3.2261 mg / mL, wogonin 0.1419 mg / mL, melaleuca alternifolia A 0.0280 mg / mL, rutin 0.0653 mg / mL, berberine hydrochloride 0.1447 mg / mL, adenosine 0.1159 mg / mL, indirubin 0.0030 mg / mL, limonin 0.1263 mg / mL, berberine 0.0103 mg / mL, gardenia glycoside 8.9997 mg / mL, chlorogenic acid 0.1432 mg / mL, and stachyose 2.0403 mg / mL.
[0232] Culture medium containing the pharmaceutical composition of Example 4: The pharmaceutical composition of Example 4 was added to 1000 mL of the above culture medium, wherein baicalein 0.0413 mg / mL, baicalin 1.3586 mg / mL, wogonin 0.046 mg / mL, melaleuca alternifolia A 0.0093 mg / mL, rutin 0.0238 mg / mL, berberine hydrochloride 0.0149 mg / mL, adenosine 0.0615 mg / mL, limonin 0.0386 mg / mL, and gardenia glycoside 3.8547 mg / mL.
[0233] Culture medium containing the pharmaceutical composition of Example 5: The pharmaceutical composition of Example 5 was added to 1000 mL of the above culture medium, wherein baicalein 0.1765 mg / mL, baicalin 2.3211 mg / mL, wogonin 0.0899 mg / mL, melaleuca alternifolia A 0.0196 mg / mL, rutin 0.0366 mg / mL, berberine hydrochloride 0.0257 mg / mL, adenosine 0.0880 mg / mL, limonin 0.0912 mg / mL, and gardenia glycoside 5.6389 mg / mL.
[0234] Culture medium containing the pharmaceutical composition of Example 6: The pharmaceutical composition of Example 6 was added to 1000 mL of the above culture medium, wherein baicalein 0.2568 mg / mL, baicalin 3.2261 mg / mL, wogonin 0.1419 mg / mL, melaleuca alternifolia A 0.0280 mg / mL, rutin 0.0653 mg / mL, berberine hydrochloride 0.1447 mg / mL, adenosine 0.1159 mg / mL, limonin 0.1263 mg / mL, and gardenia glycoside 8.9997 mg / mL.
[0235] Culture medium containing the pharmaceutical composition of DXM: DXM was added to 1000 mL of the above culture medium, wherein the final concentration of DXM was 4.4 μg / mL.
[0236] (2) Phosphate buffered saline (1× PBS): Dissolve the premixed powder in deionized water until the volume reaches 1 L, and sterilize.
[0237] Cell culture and passaging: The same as the cell culture and passaging in “Anti-inflammatory Cell Experiment 1”.
[0238] Data processing: The same as the data processing of “Anti-inflammatory Cell Experiment 1”.
[0239] 1. Changes in RAW264.7 cell morphology after LPS stimulation
[0240] A blank group (NC), a model group (LPS), different drug composition groups of the present application (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and a dexamethasone acetate positive drug group (DXM) were set up, with 2 replicates in each group.
[0241] RAW264.7 cells were seeded in 12-well plates (5×10 5 cells / well), 2 mL per well, incubated at 37°C, 5% CO 2 After 12 hours of culture, the cell supernatant was discarded, 1800 μL of fresh culture medium was added to the NC group and LPS group, and the same volume of culture medium containing the corresponding drugs was added to the different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and DXM group. After 2 hours, 200 μL of PBS was added to the NC group, and 200 μL of LPS (final concentration of 100 ng / mL) was added to the LPS group, different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and DXM group. After 16 hours of co-culture, the cells were placed on an inverted fluorescence microscope to observe the changes in cell morphology and take pictures.
[0242] The experimental results are as follows Figure 8 As shown, Figure 8Figure 2 is a diagram showing changes in the morphology of RAW264.7 cells after stimulation with lipopolysaccharide (LPS) and administration of the pharmaceutical composition of Examples 1-6 (×200 times). Figure 8 It can be seen that compared with the NC group, the RAW264.7 cells in the LPS group changed their cell morphology after LPS induction stimulation, with the cells extending tentacles and showing a polarized state; compared with the LPS group, the cell morphology of the drug-treated group improved to varying degrees. This indicates that the pharmaceutical composition provided in the present application can effectively improve the cell morphology of the LPS-induced inflammation model.
[0243] 2. Nitric oxide detection kit to test the changes in NO content in RAW264.7 cells after LPS stimulation
[0244] A blank group (NC), a model group (LPS), different drug combination groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and a dexamethasone group (DXM) were set up, with 4 replicates in each group.
[0245] RAW264.7 cells were seeded in 48-well plates (3×10 5 cells / well), 200 μL per well, incubate at 37°C, 5% CO 2 The cells were cultured for 12 h, after which the cell supernatant was discarded. 180 μL of fresh culture medium was added to the NC group and the LPS group, and the same volume of culture medium containing the corresponding drugs was added to the different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and the DXM group. After 2 h, 20 μL of PBS was added to the NC group, and 20 μL of LPS (final concentration of 100 ng / mL) was added to the LPS group, the different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and the DXM group. After 16 h of co-culture, the cell supernatant was collected and centrifuged (1000×g, 20 min), the supernatant was taken, and then the NO content was tested according to the instructions of the nitric oxide detection kit.
[0246] The experimental results are as follows Fig. 9 As shown, Fig. 9 Figure 2 is a graph showing changes in NO content in RAW264.7 cells after lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 1-6. Fig. 9 It can be seen that compared with the NC group, the amount of NO released in the LPS group was significantly increased, indicating that the inflammatory model was successfully constructed; compared with the LPS group, the expression levels of NO in the drug-treated groups were reduced to varying degrees, indicating that different drug-treated groups can effectively inhibit the release of NO in the LPS-induced inflammatory model, thereby producing a good anti-inflammatory effect.
[0247] 3. ELISA method to detect the changes in the content of inflammatory factors in RAW264.7 cells after LPS stimulation
[0248] A blank group (NC), a model group (LPS), different drug combination groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and a dexamethasone group (DXM) were set up, with 4 replicates in each group.
[0249] RAW264.7 cells were seeded in 48-well plates (3×10 5 cells / well), 200 μL per well, incubate at 37°C, 5% CO 2 The cells were cultured for 12 h, after which the cell supernatant was discarded. 180 μL of fresh culture medium was added to the NC group and the LPS group, and the same volume of culture medium containing the corresponding drugs was added to the different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and the DXM group. After 2 h, 200 μL of PBS was added to the NC group, and 20 μL of LPS (the final concentration of LPS was 100 ng / mL) was added to the LPS group, the different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and the DXM group. After 16 h of co-culture, the cell supernatant was collected and centrifuged (1000×g, 20 min), the supernatant was taken, and then the content of inflammatory factors was tested according to the instructions of the mouse IL-6, TNF-α, and IL-1β detection kit.
[0250] The experimental results are as follows Figure 10-12 As shown, Fig.10 This is a graph showing changes in the content of inflammatory factor IL-6 in RAW264.7 cells after ELISA detection of lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 1-6; Fig.11 This is a graph showing changes in the content of inflammatory factor IL-1β in RAW264.7 cells after ELISA detection of lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 1-6;
[0251] Fig.12 The graph is a graph showing the changes in the content of inflammatory factor TNF-α in RAW264.7 cells after ELISA detection of lipopolysaccharide (LPS) stimulation and administration of the pharmaceutical composition of Examples 1-6. Figure 10-12It can be seen that compared with the NC group, the content of inflammatory factors IL-6, IL-1β, and TNF-α in the LPS group was significantly higher than that in the blank group (p < 0.01), indicating that the inflammation model was successfully constructed; compared with the LPS group, the levels of inflammatory factors IL-6, IL-1β, and TNF-α in different drug composition groups (9+4-H, 9+4-M, 9+4-L, 9-H, 9-M, 9-L) and DXM groups were significantly reduced (p < 0.01). The above results show that the pharmaceutical composition provided in this application can exert a good anti-inflammatory effect.
[0252] Pharyngitis animal experiment
[0253] 1. Experimental Materials
[0254] 1. Experimental Animals
[0255] Sprague-Dawley (SD) male rats (200±20g) were purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., animal license number: SCXK (Zhejiang) 2019-0001. They were given one week of adaptive feeding before the formal experiment, during which they were free to eat and drink water. The breeding environment temperature was 24±2℃, and the light was on for 12h per day. All animal experiments were performed under the guidance of the "Regulations on the Administration of Experimental Animals" of Jiangsu Province. The experimental ethics number is 2022-09-007.
[0256] 2. Experimental reagents
[0257] Dexamethasone acetate was purchased from Zhejiang Xianju Pharmaceutical Co., Ltd.
[0258] Isoflurane was purchased from Shenzhen Ruiwode Life Science Technology Co., Ltd.
[0259] Tween 20 and ammonia were purchased from Nanjing Chemical Reagent Co., Ltd.
[0260] 4% paraformaldehyde universal tissue fixative was purchased from Biosharp Company.
[0261] Rat tumor necrosis factor-α (TNF-α) ELISA kit (ml002859), rat interleukin-6 (IL-6) ELISA kit (ml102828), and rat interleukin-1β (IL-1β) ELISA kit (ml003057) were purchased from Shanghai ELISA Biotechnology Co., Ltd.
[0262] BCA protein quantification kit, Western and IP cell lysate and RIPA lysate were purchased from Shanghai Biotech Biotechnology Co., Ltd.
[0263] Skim milk powder was purchased from Inner Mongolia Yili Industrial Group Co., Ltd.
[0264] Nitrocellulose membrane NC was purchased from Millipore.
[0265] Protein markers were purchased from Nanjing Novozymes Biotechnology Co., Ltd.
[0266] Sodium carboxymethyl cellulose, SDS, Tris, 1.5 M Tris-HCl (pH 8.8), 0.5 M Tris-HCl (pH 6.8), ready-to-use TBS powder, glycine, ammonium persulfate, tetramethylethylenediamine (TEMED), and 30% acrylamide solution were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0267] Protease inhibitors and phosphatase inhibitors were purchased from Shanghai Roche Pharmaceuticals Co., Ltd.
[0268] The primary antibodies TLR4 (mouse, sc-293072) and NF-κB p65 (mouse, sc-8008) were purchased from Santa Cruz Biotechnology.
[0269] Red loading buffer (3×, 7723) and primary antibody p-NF-κB p65 (Rabbit, 3033) were purchased from Cellsignaling technology.
[0270] Internal reference β-actin (Rabbit, 20536-1-AP), HRP-goat anti-rabbit IgG (SA00001-2) and HRP-goat anti-mouse IgG (SA00001-1) were purchased from Proteintech.
[0271] ECL chemiluminescent substrate was purchased from Shanghai Tianneng Technology Co., Ltd.
[0272] 3. Experimental instruments
[0273] ENT atomizer spray gun (Foshan Xinnuoer Medical Instrument Co., Ltd.); small animal endoscope (Shanghai Yuyan Scientific Instrument Co., Ltd.); small animal anesthesia machine (Shenzhen Ruiwode Life Science Co., Ltd.); multifunctional microplate reader (BERTHOLD TECHNOLOGIES); inverted fluorescence microscope (Nanjing Skospect Instrument Co., Ltd.); BT25S one-hundred-thousandth balance (Sartorius, Gottingen, Germany); MJXFSTPRP-24 tissue grinder (Shanghai Jingxin Industrial Development Co., Ltd.); centrifuge (Thermo Fisher Scientific (China) Co., Ltd.); 5810R high-speed refrigerated centrifuge (eppendorf); fully automatic chemiluminescence / fluorescence image analysis system (Shanghai Tianneng Technology Co., Ltd.).
[0274] 2. Experimental methods and results
[0275] Experimental groups: SD rats were divided into a blank group (NC), a model group (AP), a group of Example 7 of the pharmaceutical composition of the present application (ECS-1), a group of Example 8 (ECS-2), a group of Example 34 (ECS-3), and a dexamethasone acetate positive group (DXM).
[0276] Modeling and administration: The acute pharyngitis model of rats was prepared by stimulating the pharynx of rats with ammonia water. Ammonia water with a mass fraction of 20% was sprayed into the pharynx of rats with an ENT atomizer spray gun, once in the morning and afternoon (timing 10:00 and 16:00), 2-3 times each time, and sprayed for 3 consecutive days, so that the pharyngeal mucosa of rats became acutely red and swollen due to the stimulation of ammonia water to form an acute pharyngitis model. The blank group was sprayed with normal saline in the same way. After the modeling, the rats were randomly divided into groups, with 8 rats in each group. Starting from the 4th day, the ECS-1 group, the ECS-3 group and the ECS-2 group were gavaged at the clinical dose (5.40mL / kg), and the DXM group was gavaged at the clinical dose (1.5mg / kg), and the gavage was administered once a day for 5 consecutive days. The NC group and the AP group were replaced with normal saline.
[0277] Sampling: 2 hours after the last administration, the rat pharynx was observed and photographed with a small animal endoscope. After fasting for 12 hours overnight, the rats were anesthetized with isoflurane and whole blood and pharyngeal tissue were collected from the abdominal aorta. The blood samples were centrifuged (3500rpm, 10min) to obtain the supernatant, and some pharyngeal tissues were fixed with 4% paraformaldehyde fixative, and the remaining tissues were immediately placed in liquid nitrogen. After sampling, the samples were stored at -80°C.
[0278] 1. Evaluation of the pharyngeal appearance of rats with acute pharyngitis
[0279] The rat pharynx was photographed as follows Fig.13 As shown, Fig.13 The effect of the drug group on the pharyngeal mucosa of rats with acute pharyngitis is shown in Figure 2. Fig.13 It can be seen that: the mucosa of the NC group was smooth, light red in color, and the blood vessels were light red; compared with the NC group, the AP group had severe vascular congestion, rough mucosa, and increased saliva; compared with the AP group, the DXM group had less mucus, improved mucosal condition, and blood vessels restored to light red; compared with the AP group, the ECS-3 and ECS-1 groups had smooth mucosa, with significant improvement; compared with the AP group, the ECS-2 group had improved mucosal condition, slightly worse gloss, and slight mucus retention.
[0280] The scoring criteria for pharyngeal appearance are as follows: 0 points, pharyngeal tissue is light red, the surface is moist and shiny, there is no secretion, no congestion and other pathological phenomena; 1 point, pharyngeal tissue has poor luster and a small amount of secretion; 2 points, the tissue color becomes darker, the color is not good, and pathological phenomena such as secretion and acute congestion appear; 3 points, pharyngeal tissue is dark red, with more secretions, severe acute congestion, and pathological phenomena such as mucosal ulcers appear.
[0281] The pharyngeal appearance was scored. Fig.14 As shown, Fig.14 This is a statistical chart of the apparent score of the rat pharynx. Fig.14 It can be seen that according to the pharyngeal appearance scoring standard, the score of the AP group was significantly higher than that of the NC group; compared with the AP group, the scores of different drug administration groups were significantly reduced, indicating that the drug compositions in the drug administration groups all have the effect of improving the pharyngeal state of rats.
[0282] 2. ELISA test of the expression of inflammatory factors in the serum of rats with acute pharyngitis
[0283] The serum collected above was tested for inflammatory factors strictly according to the procedures in the instructions of each kit.
[0284] The experimental results are as follows Figure 15-17 As shown, Fig.15 This is a graph showing the effect of the drug group on the serum inflammatory factor IL-6 in rats with acute pharyngitis; Fig.16 This is a graph showing the effect of the drug group on the serum inflammatory factor IL-1β in rats with acute pharyngitis; Fig.17 The effect of the drug group on the serum inflammatory factor TNF-α in rats with acute pharyngitis. Figure 15-17 It can be seen that compared with the NC group, the expression of IL-6, TNF-α, and IL-1β inflammatory factors in the AP group was significantly increased (p < 0.01); the expression of IL-6 and TNF-α inflammatory factors in the ECS-3 group, ECS-1 group, ECS-2 group, and DXM group was significantly downregulated (p < 0.01); compared with the AP group, the expression of IL-1β inflammatory factors in the ECS-3 group and DXM group was significantly downregulated (p < 0.01), and the expression of IL-1β inflammatory factors in the ECS-1 group and ECS-2 group was significantly downregulated (p < 0.05); there was no significant difference between the ECS-1 group, the ECS-2 group, and the ECS-3 group (p > 0.05). Without being limited to any theory, the inventors of the present application believe that the pharmaceutical composition provided in the present application may play a good role in preventing acute pharyngitis by regulating the expression levels of inflammatory factors such as IL-6, TNF-α, and IL-1β.
[0285] 3. Pharyngeal histopathology of rats with acute pharyngitis
[0286] (1) Preparation of paraffin sections of pharyngeal tissue: Take out the tissue fixed with 4% paraformaldehyde for more than 48 hours, trim the target area and put it in a dehydration box. Place the dehydration box containing the tissue in the dehydrator and soak it in 75 vol% ethanol for 4 hours, 85 vol% ethanol for 2 hours, 90 vol% ethanol for 2 hours, 95 vol% ethanol for 1 hour, anhydrous ethanol twice, 30 minutes each time, alcohol benzene for 10 minutes, xylene twice, 10 minutes each time, and wax liquid for 3 hours. Then embed the wax-soaked tissue, cool and solidify the wax block in a -20℃ freezer, trim the wax block, cool it in a -20℃ freezer again, cut it into 4μm thin slices, place it in 40℃ warm water to flatten the tissue, pick up the tissue with a slide, bake it at 60℃, and store it at room temperature for later use.
[0287] (2) H&E staining: Soak the paraffin sections in xylene twice for 20 minutes each time, in anhydrous ethanol twice for 5 minutes each time, and in 75 vol% ethanol for 5 minutes, and then rinse with tap water. Then put the sections into hematoxylin staining solution for staining, wash with tap water after 5 minutes, add differentiation solution for differentiation, wash with tap water, add blueing solution for blueing, and then rinse with running water. Then soak the sections in 85 vol% ethanol and 95 vol% ethanol for 5 minutes each for gradient dehydration, and stain them in eosin staining solution for 5 minutes. After staining, soak them in anhydrous ethanol 3 times for 5 minutes each time, and in xylene 2 times for 5 minutes each time until the sections are transparent, seal the sections with neutral gum, and store the sections at room temperature.
[0288] The experimental results are as follows Fig.18 As shown, Fig.18 This is a pathological section of the pharyngeal tissue of rats with acute pharyngitis. Fig.18 It can be seen that the pharyngeal tissue mucosa layer and submucosal glands of rats in the NC group were normal; compared with the NC group, the pharyngeal tissue mucosa layer of rats in the AP group was thickened, a large number of inflammatory cells gathered in the submucosal layer, the glands were enlarged, and the muscular fibers were destroyed; the pharyngeal tissue mucosa layer of rats in the DXM group was thinned, a small amount of inflammatory cells infiltration was seen in the submucosal layer, the glands were basically normal, and the muscular fibers were improved; the pharyngeal tissue mucosa layer of rats in the ECS-3 group was basically normal, the inflammatory cells in the submucosal layer were significantly reduced, and the glands were reduced; the pharyngeal tissue mucosa layer of rats in the ECS-1 group was improved, the submucosal glands were reduced, the inflammatory cells were reduced, and the arrangement of the muscular fibers was basically restored; the pharyngeal tissue mucosa epithelium of rats in the ECS-2 group was basically flat, the inflammatory cells in the submucosal layer were reduced, and the arrangement of the muscular fibers was basically restored. It shows that the drug composition in each administration group can improve the pathological state of the pharyngeal tissue of rats with acute pharyngitis to varying degrees.
[0289] 4. Western blot analysis of the expression of related proteins in the pharyngeal tissue of rats with acute pharyngitis
[0290] Weigh 20 mg of pharyngeal tissue, place it in a 1.5 mL centrifuge tube, add magnetic beads, and then add 200 μL of lysis buffer (RIPA lysis buffer: 100× protease inhibitor: 100× phosphatase inhibitor volume ratio is 100:1:1), grind in a tissue grinder (frequency 55 Hz, grind 55 s, interrupt 10 s, grind 5 times), place at 4°C for lysis for 30 min, centrifuge the lysate at 12000 r / min in a 4°C precooled centrifuge for 10 min, and take the supernatant. The protein concentration was determined using a BCA protein quantification kit, and a certain proportion of 3× protein loading buffer was added to the quantified protein sample to dilute the buffer to 1×, denature at 100°C for 15 min, and store at -80°C. Western blot was used to detect the expression of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 proteins in pharyngeal tissues. According to the quantitative sample protein concentration, 15 μg of protein was loaded per well, and electrophoresis was performed at 80 V for 30 min, then transferred to 120 V for 1 h, and transferred to the membrane at 350 mA for 1 h. The membrane was blocked with 5% (w / v) skim milk powder at 4°C, and the primary antibody was diluted in proportion and incubated at 4°C overnight. The membrane was washed with TBST for 3×10 min the next day, and the secondary antibody was diluted in proportion and incubated at 4°C. After washing the membrane with TBST buffer, ECL supersensitive luminescent liquid was added, and the protein signals of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 were collected in a dark room.
[0291] The experimental results are as follows Fig.19 As shown, Fig.19 This is a graph showing the protein expression levels of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 in the pharyngeal tissue of rats with acute pharyngitis analyzed by Western blot. Fig. 20 This is a quantitative graph of the protein expression of β-actin, TLR4, NF-κB p65 and p-NF-κB p65 in the pharyngeal tissue of rats with acute pharyngitis analyzed by Western blot. Fig. 20 The p-NF-κB p65 / NF-κB p65 shown in the figure is the ratio of p-NF-κB p65 to NF-κB p65. β-actin is an internal reference and its ratio is used to determine the amount of protein. Fig.19 and Fig. 20It can be seen that compared with the NC group, the expression of TLR4 and p-NF-κBp65 proteins in the AP group was significantly upregulated (p < 0.05); compared with the AP group, the expression of TLR4 and p-NF-κB p65 proteins in the ECS-3 group, ECS-1 group, ECS-2 group and DXM group was inhibited (p < 0.05), and the inhibitory effects of the ECS-3 group, ECS-1 group and ECS-2 group were basically the same. Without being limited to any theory, the inventors of the present application believe that the anti-acute pharyngitis effect of each component group in the pharmaceutical composition provided in the present application may be related to the inhibition of the TLR4 / NF-κB signaling pathway in RAW264.7 cells.
[0292] The above test results show that the pharmaceutical composition of the present application has the effect of improving acute pharyngitis and can inhibit the expression of inflammatory factors TNF-α, IL-6, and IL-1β in the serum of rats with acute pharyngitis; in addition, the pharmaceutical composition of the present application can inhibit the expression of TLR4 and p-NF-κB p65 key proteins in pharyngeal tissue. Without being limited to any theory, the inventors of the present application believe that the anti-acute pharyngitis effect of the pharmaceutical composition provided by the present application may be achieved by inhibiting the activation of the TLR4 / NF-κB signaling pathway.
[0293] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.
Claims
1. A pharmaceutical composition for preparing a drug for preventing and / or treating upper respiratory tract infection, It is characterized in that The invention comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, and 49.07-74.99 parts by weight of iridoid glycosides; wherein the flavonoids comprise baicalein, baicalin, wogonin, rutin, and melaleucain A in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02); the alkaloids comprise berberine hydrochloride and adenosine in a weight ratio of 1:(1.0-5.0); the limonoids comprise limonin; and the iridoid glycosides comprise gardeniain.
2. A pharmaceutical composition for preparing a drug for preventing and / or treating upper respiratory tract infection, It is characterized in that The pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the weight ratio of the flavonoids is (0.025-0.1):1:(0.03-0.06):(0.01 -0.03):(0.005-0.02) of baicalein, baicalin, wogonin, rutin and melaleuca alternifolia A; the alkaloids contain berberine hydrochloride, adenosine and indirubin in a weight ratio of 1:(1.0-5.0):(0.01-0.1); the limonoids contain limonin and berberine in a weight ratio of (12-27):1; the iridoid glycosides contain gardenia glycoside; the organic acids contain chlorogenic acid; the sugars contain stachyose.
3. A pharmaceutical composition for preparing a drug for preventing and / or treating upper respiratory tract infection, It is characterized in that The pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the weight ratio of the flavonoids is (0.025-0 .1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02):(0.01-0.03):(0.002-0.007):(0.004-0.02):(0.008-0.02):(0.004-0.01) of baicalin, baicalin, wogonin, rutin, melaleucalycin A, chrysin-7 -O-β-D-glucuronide, isoquercetin, scutellarin, baicalin and scutellariae flavonoids II; the alkaloids contain a weight ratio of 1: (0.735-5.0): (0.005-0.12): (0.5-4.5): (0.4-3.5): (0.024-0.2): (0.015-0.15): (0.35-2.5): (0. 33-2.0) of berberine hydrochloride, adenosine, indirubin, phellodendron hydrochloride, magnolamine, palmatine hydrochloride, jatrorrhizine hydrochloride, uridine and guanosine; the limonoids contain limonin and phellodendron ketone in a weight ratio of (12-28.5):1; the iridoid glycosides contain gardenia glycoside; the organic acids contain chlorogenic acid and ferulic acid in a weight ratio of (4-12):1; the sugars contain stachyose.
4. A pharmaceutical composition for preparing a drug for preventing and / or treating upper respiratory tract infection, It is characterized in that The pharmaceutical composition comprises: 19.74-32.40 parts by weight of flavonoids, 1.35-4.49 parts by weight of alkaloids, 0.5-1.14 parts by weight of limonoids, 49.07-74.99 parts by weight of iridoid glycosides, 0.49-1.30 parts by weight of organic acids, and 5.49-17 parts by weight of sugars; wherein the flavonoid component comprises baicalein, baicalin, wogonin, rutin, melaleuca alternifolia A, and chrysin-7-O-β-D-glucose in a weight ratio of (0.025-0.1):1:(0.03-0.06):(0.01-0.03):(0.005-0.02):(0.01-0.03):(0.008-0.02):(0.004-0.01). The invention discloses a novel ...
5. The pharmaceutical composition according to any one of claims 1 to 4, It is characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.
6. The pharmaceutical composition according to claim 5, It is characterized in that The pharmaceutical composition is prepared into a pharmaceutically acceptable preparation, and the dosage form of the preparation includes capsules, oral liquids, tablets, granules or pills.
7. Use of the pharmaceutical composition according to any one of claims 1 to 6 in the preparation of a medicament for preventing and / or treating upper respiratory tract infection.
8. The use according to claim 7, It is characterized in that The upper respiratory tract infection includes colds, pharyngitis, laryngitis, pharyngitis, and tonsillitis; wherein the pharyngitis includes acute pharyngitis, chronic pharyngitis, viral pharyngitis, and bacterial pharyngitis; the laryngitis includes acute laryngitis, chronic laryngitis, viral laryngitis, and bacterial laryngitis; the pharyngitis includes herpetic pharyngitis; the tonsillitis includes acute tonsillitis, chronic tonsillitis, viral tonsillitis, and bacterial tonsillitis.
